Press Release: Ionis to hold first quarter 2025 financial results webcast

Dow Jones

04-16

Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time

CARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025--

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/

 
    CONTACT:    Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer -- media@ionis.com -- 760-603-4679

(END) Dow Jones Newswires

April 16, 2025 07:08 ET (11:08 GMT)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2527294049"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527294049\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2527294049?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-16 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527294049","market":"sg","top_or_hot":-1,"title":"Press Release: Ionis to hold first quarter 2025 financial results webcast","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time \n</p>\n<pre>\nCARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025-- \n</pre>\n<p>\n     <a href=\"https://laohu8.com/S/IONS\">Ionis Pharmaceuticals, Inc</a>. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. \n</p>\n<p>\n     The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. \n</p>\n<p>\n     About Ionis Pharmaceuticals, Inc. \n</p>\n<p>\n     For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/ \n</p>\n<pre>\n \n    CONTACT:    Ionis Pharmaceuticals Investor Contact: \n</pre>\n<p>\n     D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331 \n</p>\n<p>\n     Ionis Pharmaceuticals Media Contact: \n</p>\n<p>\n     Hayley Soffer -- media@ionis.com -- 760-603-4679 \n</p>\n<pre>\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 07:08 ET (11:08 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Ionis to hold first quarter 2025 financial results webcast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Ionis to hold first quarter 2025 financial results webcast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-16 19:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time \n</p>\n<pre>\nCARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025-- \n</pre>\n<p>\n     <a href=\"https://laohu8.com/S/IONS\">Ionis Pharmaceuticals, Inc</a>. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. \n</p>\n<p>\n     The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. \n</p>\n<p>\n     About Ionis Pharmaceuticals, Inc. \n</p>\n<p>\n     For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/ \n</p>\n<pre>\n \n    CONTACT:    Ionis Pharmaceuticals Investor Contact: \n</pre>\n<p>\n     D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331 \n</p>\n<p>\n     Ionis Pharmaceuticals Media Contact: \n</p>\n<p>\n     Hayley Soffer -- media@ionis.com -- 760-603-4679 \n</p>\n<pre>\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 07:08 ET (11:08 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2527294049","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527294049","pubTimestamp":1744801680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time. Ionis Pharmaceuticals, Inc.  announced today that it will host a live webcast on Wednesday, April 30 at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X , LinkedIn and Instagram.D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"新闻稿：Ionis将举行2025年第一季度财务业绩网络广播","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time \n\n\nCARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025-- \n\n\nIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. \n\n\n     The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. \n\n\n     About Ionis Pharmaceuticals, Inc. \n\n\n     For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. \n\n\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/ \n\n\n \n    CONTACT:    Ionis Pharmaceuticals Investor Contact: \n\n\n     D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331 \n\n\n     Ionis Pharmaceuticals Media Contact: \n\n\n     Hayley Soffer -- media@ionis.com -- 760-603-4679 \n\n\n \n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 07:08 ET (11:08 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}